Stérilisation du furet avec un analogue de la GnRH

Stérilisation du furet
avec un analogue de la GnRH
Didier Boussarie
EN SAVOIR PLUS SUR LE FURET
EN SAVOIR PLUS
- Bielinska M, Khveri S, Parviainen H et coll.
Gonadectomy-induced adrenocortical
neoplasia in the ferret (Mustela putorius
furo) and laboratory Mouse. Vet. Pathol.
2006;43(2):97-117.
- Boussarie D. Guide pratique de médecine
du furet. Med’Com, Paris. 2007:286p.
- Herbert CA, Trigg TE, Renfree MB et coll.
Long-term effect of deslorin implants on
reproduction in the female tammar
wallaby (Macropus eugeni). Reprod.
2005;129(3):361-369.
- Johnson-Delaney C. Update of ferret
adrenal disease: etiology, diagnosis and
treatment. AEMV Proceeding, 2006.
- Junaidi A, Williamson PE, Cummins JM et
coll. Use of a new drug delivery formulation
of the gonadotrophin-releasing hormone
analogue Deslorin for reversible long-term
contraception in male dog. Reprod. Fertility
Develop. 2003;15:317-322.
- Marin GB, Doyle AG, Walsh J. Use of a
GnRH analogue implant to produce
reversible long-term suppression of
reproduction function in male and female
domestic dogs. J. Reprod. Fertility Suppl.
2001;57:255-261.
- Muller A, Quinton JF, Chetboul V et coll.
Hypercorticisme chez un furet. Prat. Med.
Chir. Anim. Comp. 2001;36:43-53.
- Piazza S. Utilisation du Suprelorin®
comme alternative à la stérilisation
chirurgicale chez le furet. Prat. Anim. Sauv.
Exot. 2009,9(1):3-6.
- Quesenberry K, Rosenthal K. Endocrines
diseases. In: Quesenberry KE, Carpenter JW
(eds). Ferrets, Rabbits and Rodents: Clinical
medicine and surgery. WB Saunders, New
York. 2e ed. 2004:79-90.
- Schoemaker NJ, Schurmans M, Moorman
H et coll. Correlation between age at
neutering and age at onset of
hyperadrenocorticism in ferrets, J. Am. Vet.
Med. Assoc. 2000;216(2):195-197.
- Schoemaker NJ, Lumeij JT, Rijnberk A.
Current and future option for non surgical
neutering of ferrets (Mustela putorius furo).
In: Schoemaker NJ (eds).
Hyperadrenocorticism in ferrets.
Department of Clinical Sciences of
Companion Animals, Utrecht University.
2003:131-144.
- Schoemaker NJ, Teerds KL, Mol JA and coll.
The role of luteinising hormone in the
pathogenesis of hyperadrenocorticism in
neutered ferrets. EJCAP. 2004;14:69-76.
- Schoemaker NJ, Kuijten A, Moorman H et
coll. Alternative à la castration des furets
(traduction). Frettensymposium, Maarssen,
28 octobre 2006.
- Trigg TE, Doyle AG, Walsh JD et coll. A
rewiew of advance in the use of the GnRH
agonist deslorelin in control of
reproduction. Theriogenol.
2006;66:1507-1512.
- Wagner RA, Piche CA, Jochle W et coll.
Clinical and endocrine responses to
treatment with deslorelin acetate implant
in ferrets with adrenocortical disease. AJVR.
2005;66(5):910-914.
- Wagner RA. The treatment of adrenal
cortical disease in ferrets with 4,7 mg
deslorin acetate implants. J. Exotic Pract.
Med. 2009;18(2):146-152.
- Boussarie D. Consultation du furet.
Dans : Encyclopédie vétérinaire. Médecine
générale, 3000. Ed. Elsevier Masson SAS,
Paris. 2008:21p.
- Boussarie D. Guide des maladies du
furet. Med’Com, Paris. 2007.
- Boussarie D. Le furet. Dans : Legeay Y,
Moraillon R, Boussarie D (eds). Guide
thérapeutique des chiens, chats, NAC.
Masson, Paris. 2007:751-800.
- Boussarie D. Mémento thérapeutique
des NAC. Med’Com, Paris. 2003:150p.
- Boussarie D. Le furet. Dans : Boussarie D,
Schilliger L, Rival F (eds). Vade-mecum
d’anesthésie des NAC. Med’Com, Paris.
2002:26-29.
- Fox J. Disease of the ferret. Lea and
Febiger, Philadelphie. 1998.
- O’Malley B. Ferret. In: O’Malley, ed.
Clinical anatomy and physiology of exotic
species. Elsevier Saunders, Londres.
2005:237-261.
- Quesenberry K. Carpenter J. Ferrets,
rabbits and rodents. Clinical Medicine and
Surgery. 2nd ed. Elsevier-Saunders, St Louis.
2004:496p.
- Silverman S, Tell L. Radiology of rodents,
rabbits and ferrets. An Atlas of normal
anatomy and positioning. Elsevier
Saunders, St Louis. 2005:352p.
SITES INTERNET
• http://www.peptech.com/HTML/
Animal_Health/Suprelorin_general.html
• http///emea.europea.eu/vetdocs/verts/
Epar/suprelorin/suprelorin.html
Ce site contient un résumé des
caractéristiques de Suprelorin® et le
Rapport européen public d’évaluation
(EPAR).